Quest Diagnostics Inc

Guardant Health (GH) is gaining attention after new COSMOS-MEL01 data showcased the high specificity and sensitivity of its Guardant Reveal blood test for detecting molecular residual disease and melanoma recurrence. Despite recent share price gains, the company's valuation is seen as 18% undervalued by some analysts, with a fair value of around $199.04. However, others argue that its current P/S ratio of 18.5x, significantly higher than the sector average, implies a heavy premium for future growth, raising questions about whether the company can grow into this valuation before market sentiment shifts.

Labcorp has launched the new Thrive 5 Health Test in collaboration with Thrive Global. This article is reserved for members and provides key information on recent activities of Labcorp Holdings Inc., including analyst price target adjustments and insights into the pharma sector's increasing use of AI. Labcorp is set to release its Q3 2026 earnings on October 28.

Argus provided a report on Celsius Holdings, Inc. (CELH), noting that the company operates in the energy drink market with 95% of its revenue from North America. The report is dated October 7, 2026, and mentions a current stock price of $27.98. Users can upgrade for premium screener tools and detailed company profiles.

Google is enhancing its health data capabilities by partnering with Function Health, integrating over 160 lab tests with wearable data to provide a more comprehensive health picture to users. This move aims to deepen engagement with Google's health ecosystem and devices, directly challenging Apple's recent Health app overhaul which also focuses on AI-powered insights and lab test integration. The competition highlights both companies' efforts to transform fragmented health information into personalized guidance, with engagement and user trust in data handling being key factors for success.

Argus lowered its target price for NeoGenomics, Inc. (NEO) to $17.00. The company provides oncology diagnostic testing and consultative services, including laboratory services and professional interpretation of test results. Investors can upgrade to premium research reports for detailed company profiles and trade insights.

Argus has raised its target price for DaVita Inc. (DVA) to $189.00. DaVita is identified as the largest provider of dialysis services in the United States, holding approximately 35% market share based on the number of clinics. The report provides an earnings estimate and a current stock price of $181.78.

Quest Diagnostics (DGX) is trading at $230.97, showing strong year-to-date gains of 36.3% despite minimal daily movement. The company consistently beats earnings expectations and saw accelerated revenue growth in 2025. While fundamentals are strong, technical indicators suggest short-term bearishness, with the stock near its pivot point support.

Guardant Health (GH) has seen significant stock gains over the past three years, prompting a look into whether its cash flows justify its current share price of around US$167. A Discounted Cash Flow (DCF) model suggests Guardant Health's estimated intrinsic worth is meaningfully above its current share price, implying it's relatively expensive on near-term losses but undervalues its longer-term cash flow potential. This valuation hinges on the company's ability to transition from current cash outflows to sustained inflows through scaling its testing portfolio, supported by recent approvals and clinical data.

This article announces personnel updates at several companies in the precision medicine and diagnostics sector. It mentions news concerning appointments or changes at 3billion, Quest Diagnostics, Alamar Biosciences, and NeoGenomics.

This article provides stock information and recent news for Zevra Therapeutics Inc. (ZVRA-Q), a rare disease company. It includes real-time stock data, a summary of recent analyst ratings with "Buy" recommendations from various firms, and news releases regarding clinical data publications and patent listings. The company profile highlights its focus on developing transformational therapies for diseases with limited treatment options.